Thanks, Alan. First off, with regard to the presidential and congressional election results, we would note that this is the first election cycle in U.S. history where both presidential candidates have supported cannabis reform. While tentative results of the presidential election indicate that Donald Trump has received the necessary electoral votes as well as the Republican Senate and a house that is skewing Republican, we note, of course, the continuing strong and growing bipartisan support for cans reform at the federal level and remain optimistic on that front. Presumed President-elect Trump's recent remarks in September on federal cannabis reform are also encouraging with a focus on safe banking for state-authorized companies and supporting states’ rights for passing and operating regulated cannabis programs. That said, the path forward on meaningful cans reform at the federal level does narrow in our view in the near term, assuming the current expected results hold. Looking at state voting results, four states had cannabis legalization matters on their ballots in the election cycle, including adult-use programs for Florida, South Dakota and North Dakota and medical use for Nebraska. In Florida, while Amendment 3 received majority support from voters, it failed to receive the requisite 60% voter support to legalize adult-use cannabis despite the previous support from Donald Trump. Both North Dakota and South Dakota also failed to pass their adult-use cannabis referendums. Finally, Nebraska voters approved the adoption of a medical-use cannabis program with more than 2/3 support, reflecting, again, the large majority support for medical cannabis shown in polls of Nebraska residence. Assuming the ongoing legal challenges regarding signature for ballot access are rejected, Nebraska will join the overwhelming majority of states that have adopted a medical-use cannabis program. And in Minnesota, it has been quite some time coming, but the state's Office of Cannabis Management expects to finalize rules for the adult-use program in the first quarter of 2025 with the expectation of commencing adult-use operations shortly thereafter. Regarding the DEA's progress on rescheduling cannabis from Schedule 1 to Schedule 3, we will, of course, be closely watching the administrative hearing on the matter, which was recently postponed from December 2 to a date likely in early 2025. Visibility on rescheduling continues to be murky, factoring in the administrative hearing and the tens of thousands of comments received from the public. Nonetheless, we remain cautiously optimistic that rescheduling will continue to make forward progress. Looking to the general market dynamics, while we continue to see positive incremental steps toward additional state programs coming online and more efforts to combat the illicit markets, we do see continued financial pressure on licensed cannabis markets having to compete with the untaxed, unregulated and historically unchecked illicit market, especially since inflationary pressures have made consumers all the more cost conscious. To give a sense of the magnitude of the illicit market in certain states, while difficult to measure, it is estimated that the California illicit market alone is a $10 billion industry. And while California authorities recently announced the seizures or eradication of over $500 million of illicit cannabis year-to-date, that amounts to a mere 5% of the total estimated size of the illicit market. That said, we are seeing some progress in certain states and localities that have shifted priorities to more meaningful enforcement against illicit operators. In New York, for example, pursuant to legislation passed last year, and increased civil and tax penalties on license sales of cannabis and provided additional enforcement powered authorities. New York has seen a significant uptick in enforcement actions in the illicit market, which we believe have also contributed to a strengthening of the license market, which is on pace to potentially exceed $1 billion in regulated adult-use sales in 2024. From a capital raising and M&A perspective, while the regulated cannabis industry continues to be challenged, we are seeing signs of more activity in the debt markets for MSO refinancing most recently evidenced by our tenant Ascent's Q3 closing on a private placement of $235 million of senior secured notes due in 2029. Of course, we are closely following developments and monitoring execution of refinancing plans for a number of MSOs that have debt maturities in the coming few years, with the bulk of those maturities coming in 2026. I'd like to now turn the call over to Ben to discuss our investment and leasing activity in Q3 and year-to-date. Ben?